| Literature DB >> 34851994 |
Eiji Iwata1,2, Junya Kusumoto2, Naoki Takata1, Shungo Furudoi3, Akira Tachibana1, Masaya Akashi2.
Abstract
BACKGROUND: Necrotizing fasciitis (NF) is an acute and life-threatening soft-tissue infection however rarely seen in oro-cervical region. Therefore, the details of oro-cervical NF (OCNF) are not well known. The purpose of this study was to investigate the characteristics of OCNF by comparing it with severe cellulitis of oro-cervical region (OCSC) or NF of other body regions (e.g., limb, perineum, and trunk) (BNF), respectively.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34851994 PMCID: PMC8635337 DOI: 10.1371/journal.pone.0260740
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
LRINEC score.
| Variable | Value | Points |
|---|---|---|
| CRP (mg/dL) | ≥15 | 4 |
| WBC (/μL) | ≥15,000 | 1 |
| >25,000 | 2 | |
| Hb (g/dL) | <13.5 | 1 |
| <11.0 | 2 | |
| Na (mmol/dL) | <135 | 2 |
| Cr (mg/dL) | >1.59 | 2 |
| Glu (mg/dL) | >180 | 1 |
Clinical features of NF as the disease progress through clinical stages.
| Stage 1 (Early) | Stage 2 (intermediate) | Stage 3 (Late) |
|---|---|---|
| Tenderness to palpation (extending beyond the apparent area of skin involvement) | Blister or bullae formation (serious fluid) | Hemorrhagic bullae |
| Skin anesthesia | ||
| Erythema | Skin fluctuance | Crepitus |
| Swelling | Skin induration | Skin necrosis with dusky discoloration progressing to frank gangrene |
| Warm to palpation |
Results of univariate analysis of the risk factors for OCNF in OCSI patients.
| Variables | OCNF group | OCSC group | ||
|---|---|---|---|---|
| (n = 14) | (n = 217) | |||
| Sex | Male | 5 (35.7) | 110 (50.7) | 0.409 α |
| Female | 9 (64.3) | 107 (49.3) | ||
| Age | Mean ± SD | 69.1 ± 17.3 | 56.0± 21.2 | 0.022* β |
| BMI | Mean ± SD | 21.9 ± 3.6 | 22.9 ± 4.0 | 0.349 β |
| Compromised host | No | 6 (42.9) | 160 (73.7) | 0.026* α |
| Yes | 8 (57.1) | 57 (26.3) | ||
| CK (U/L) | Mean ± SD | 247.3 ± 608.2 | 115.1 ± 178.7 | 0.599 β |
| Male | Mean ± SD | 604.0 ± 976.3 | 137.6 ± 211.8 | 0.046* β |
| Female | Mean ± SD | 49.1 ± 26.9 | 92.0 ± 133.8 | 0.102 β |
| CRP (mg/dL) | Mean ± SD | 26.4 ± 10.2 | 10.0 ± 5.9 | <0.001* β |
| WBC (103/μL) | Mean ± SD | 22.5 ± 10.6 | 12.4 ± 3.6 | <0.001* β |
| Hb (g/dL) | Mean ± SD | 11.7 ± 1.6 | 13.5 ± 1.8 | 0.001* β |
| Male | Mean ± SD | 12.6 ± 1.4 | 14.3 ± 1.6 | 0.022* β |
| Female | Mean ± SD | 11.2 ± 1.6 | 12.6 ± 1.6 | 0.022* β |
| Na (mmol/L) | Mean ± SD | 137.2 ± 4.6 | 138.3 ± 5.1 | 0.394 β |
| Cr (mg/dL) | Mean ± SD | 1.2 ± 0.6 | 0.9 ± 0.5 | 0.043* β |
| Male | Mean ± SD | 1.3 ± 0.5 | 0.9 ± 0.4 | 0.019* β |
| Female | Mean ± SD | 1.0 ± 0.7 | 0.9 ± 1.3 | 0.394 β |
| Glu (mg/dL) | Mean ± SD | 138.6 ± 51.1 | 125.7 ± 45.6 | 0.066 β |
| NLR | <15.3 (cut off value) | 1 (7.1) | 195 (89.9) | <0.001* β |
| ≥15.3 | 13 (92.9) | 22 (10.1) | ||
| LRINEC score | <6 points (cut off value) | 4 (28.6) | 203 (93.5) | <0.001* α |
| ≥6 points | 10 (71.4) | 14 (6.5) | ||
| Hospitalization periods (days) | Mean ± SD | 24.3 ± 14.2 | 9.6 ± 6.3 | <0.001* β |
| Outcomes | Survival | 13 (92.3) | 217 (100.0) | 1.000 α |
| Mortality | 1 (7.7) | 0 (0.0) |
Values are expressed as absolute numbers, with the corresponding percentage of the total in parentheses. Values in the right-hand column indicate the statistical significance of the difference between subgroups. Most variables expressed as the mean ± standard deviation in a parametric ratio scale.
α: Fisher’s exact test; β: Mann–Whitney U test; γ: Chi-squared test. * P < 0.05.
Fig 1(A) The ROC curve for accuracy of NLR in predicting the presence of OCNF in OCSI patients. The AUC for our model was 0.944 (95% confidence interval 0.907 to 0.982). (B) The ROC curve for accuracy of LRINEC score in predicting the presence of OCNF in OCSI patients. The AUC for our model was 0.938 (95% confidence interval 0.889 to 0.987).
The results of the multivariate logistic regression analysis of the risk factors for OCNF in OCSI patients.
| 95% CI | ||||
|---|---|---|---|---|
| Variable | P value | Odds ratio | Lower | Upper |
| NLR ≥15.3 | <0.001 | 63.5 | 7.4 | 545.7 |
| LRINEC score ≥6 points | 0.001 | 14.8 | 3.1 | 69.7 |
CI. Confidence interval.
Data are the p-value, odds ratio and 95% confidence interval (CI) for those factors found to be significantly associated with an increased risk of OCNF.
Comparison of OCNF group and BNF group.
| Variables | OCNF group | BNF group | ||
|---|---|---|---|---|
| (n = 14) | (n = 17) | |||
| Site of infection | Lower limb | ― | 8 (47.1) | ― γ |
| Upper limb | ― | 3 (17.6) | ||
| Perineum | ― | 5 (29.4) | ||
| Trunk | ― | 1 (5.9) | ||
| Maxilla | 1 (7.7) | ― | ||
| Mandible | 13 (92.3) | ― | ||
| Sex | Male | 5 (35.7) | 9 (52.9) | 0.473 α |
| Female | 9 (64.3) | 8 (47.1) | ||
| Age | Mean ± SD | 69.1 ± 17.3 | 63.8 ± 18.4 | 0.444 β |
| BMI | Mean ± SD | 21.9 ± 3.6 | 21.9 ± 2.3 | 0.830 β |
| Compromised host | No | 6 (42.9) | 12 (70.6) | 0.157 α |
| Yes | 8 (57.1) | 5 (29.4) | ||
| CK (U/L) | Mean ± SD | 247.3 ± 608.2 | 350.0 ± 638.8 | 0.336 β |
| Male | Mean ± SD | 604.0 ± 976.3 | 176.1 ± 246.8 | 0.190 β |
| Female | Mean ± SD | 49.1 ± 26.9 | 545.4 ± 883.5 | 0.059 β |
| CRP (mg/dL) | Mean ± SD | 26.4 ± 10.2 | 18.8 ± 10.2 | 0.044 |
| WBC (103/μL) | Mean ± SD | 22.5 ± 10.6 | 13.5 ± 6.6 | 0.021 |
| Hb (g/dL) | Mean ± SD | 11.7 ± 1.6 | 11.5 ± 2.2 | 0.739 β |
| Male | Mean ± SD | 12.6 ± 1.4 | 11.3 ± 2.7 | 0.240 β |
| Female | Mean ± SD | 11.2 ± 1.6 | 11.8 ± 1.7 | 0.370 β |
| Na (mmol/L) | Mean ± SD | 137.2 ± 4.6 | 133.9 ± 5.3 | 0.071 β |
| Cr (mg/dL) | Mean ± SD | 1.2 ± 0.6 | 2.4 ± 3.0 | 0.377 β |
| Male | Mean ± SD | 1.3 ± 0.5 | 3.0 ± 3.7 | 0.898 β |
| Female | Mean ± SD | 1.0 ± 0.7 | 1.8 ± 2.0 | 0.423 β |
| Glu (mg/dL) | Mean ± SD | 138.6 ± 51.1 | 167.7 ± 134.5 | 0.625 β |
| NLR | Mean ± SD | 26.0 ± 14.0 | 24.6 ± 18.6 | 0.468 β |
| LRINEC score | <6 points | 4 (28.6) | 7 (41.1) | 0.423 α |
| ≥6 points | 10 (71.4) | 10 (58.9) | ||
| Gas production | No | 9 (64.3) | 14 (82.4) | 0.412 α |
| Yes | 5 (35.7) | 3 (17.6) | ||
| Clinical stages | Stage 1 | 14 (100.0) | 6 (35.3) | <0.001 |
| Stage 2 | 0 (0.0) | 4 (23.5) | ||
| Stage 3 | 0 (0.0) | 7 (41.2) | ||
| Hospitalization periods (days) | Mean ± SD | 24.3 ± 14.2 | 30.1 ± 19.9 | 0.376 β |
| Outcomes | Survival | 13 (92.3) | 11 (64.7) | 0.073 α |
| Mortality | 1 (7.7) | 6 (35.3) |
Values are expressed as absolute numbers, with the corresponding percentage of the total in parentheses. Values in the right-hand column indicate the statistical significance of the difference between subgroups. Most variables expressed as the mean ± standard deviation in a parametric ratio scale.
α: Fisher’s exact test; β: Mann–Whitney U test; γ: Chi-squared test.
* P < 0.05.